What does this research mean for the field?

The recombinant C-terminal variant of the novel antigen Eg174 (rEg174-CT) provides significant immunoprotection against Echinococcus granulosus infection in mice by inducing strong Th1/Th17-biased immune responses. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the immunogenicity and protective efficacy of full-length and C-terminal recombinant splice variants of candidate antigen Eg174 against Echinococcus granulosus in a murine model.

August 27, 2026Parasites & VectorsOpen Access

Immunogenicity and protective efficacy of the novel candidate antigen Eg174 against Echinococcus granulosus infection in a murine model

View Full Paper

Ask AI

Bookmark

Authors

YHYushu HeJilin University XHXiaoying HeJilin University XWXiaoxia WuChinese PLA General Hospital

Discussion

Member takes

Implication

Experimental animal study demonstrates enhanced immunoprotection and Th1/Th17 immune responses with recombinant Eg174-CT in mice, highlighting its potential as a vaccine candidate.

Key Points

To evaluate the immunogenicity and protective efficacy of full-length and C-terminal recombinant splice variants of candidate antigen Eg174 against Echinococcus granulosus in a murine model.
Generated recombinant proteins rEg174-FL (full-length) and rEg174-CT (C-terminal) via prokaryotic expression.
Immunized ICR mice with the recombinant proteins and evaluated protective efficacy using liver cyst counts after protoscolex challenge and in vitro parasite killing assays.
Measured humoral antibody responses (total IgG, IgG1, IgG2a) using ELISA and cellular cytokine responses (IFN-γ, IL-17A, TNF-α) using flow cytometry.
Mice immunized with rEg174-CT exhibited a significantly higher cyst reduction rate following protoscolex challenge compared to mice receiving rEg174-FL.
rEg174-CT induced a stronger Th1-biased humoral response, marked by higher total IgG titers and a higher ratio of IgG2a to IgG1.
Cellular immune analysis demonstrated that rEg174-CT stimulated stronger and more sustained Th1/Th17-biased cytokine production, including elevated IFN-γ, IL-17A, and TNF-α.

Cite This Study

He et al. (2026) studied this question.

synapsesocial.com/papers/6a8fe99110c91c1e926212a6 https://doi.org/10.1186/s13071-026-07614-8

View Full Paper

Ask AI

Bookmark

Implication

Experimental animal study demonstrates enhanced immunoprotection and Th1/Th17 immune responses with recombinant Eg174-CT in mice, highlighting its potential as a vaccine candidate.

Immunogenicity and protective efficacy of the novel candidate antigen Eg174 against Echinococcus granulosus infection in a murine model

Discussion

Member takes

Implication

Key Points

Cite This Study

Immunogenicity and protective efficacy of the novel candidate antigen Eg174 against Echinococcus granulosus infection in a murine model

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider